Pre-clinical work using MSCs modified to express different forms of TRAIL have been shown to have therapeutic efficacy in pre-clinical models of mesothelioma [26], [72], lung metastases [25], breast cancer [89], cervical cancer [90], myeloma [91] and glioma [22]. Here, TNFSF10 is linked to mesothelioma.